We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TGTX shares rose after preliminary Q4 and full-year 2025 revenues topped company guidance.
TGTX expects 2026 revenues of $875M to $900M, including $825M to $850M from U.S. Briumvi sales.
TGTX plans multiple 2026 milestones, including ENHANCE data, subcutaneous Briumvi results, and azer-cel data.
TG Therapeutics’ (TGTX - Free Report) shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations.
TGTX issued bullish guidance for 2026 and outlined some key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates.
TG Therapeutics’ top line primarily comprises product sales from Briumvi, along with royalty and other revenues. Briumvi is approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
Over the past year, TG Therapeutics shares have declined 7.7% against the industry’s growth of 18.7%.
Image Source: Zacks Investment Research
Q4 & FY2025 Preliminary Results
TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, exceeding the guidance of $600 million, provided with the third-quarter 2025 earnings release in November. The preliminary sales number also beat the Zacks Consensus Estimate of $604 million.
Briumvi U.S. net product revenues are expected to be approximately $182 million for the fourth quarter of 2025.
For full-year 2025, Briumvi net product sales are expected to be around $594 million in the United States, surpassing the company’s November guidance of around $585 million.
TGTX's 2026 Outlook & Pipeline Goals
TG Therapeutics expects worldwide total revenues in the range of $875 million to $900 million in 2026, including net product revenues of approximately $825 million to $850 million from Briumvi sales in the United States. The 2026 guidance range indicates potential double-digit year-over-year growth compared with the expected 2025 numbers.
TGTX expects operating expenses of around $350 million for the full year 2026.
In 2026, TGTX expects to advance several key milestones across its development pipeline. It recently completed patient enrollment in the phase III ENHANCE study which is evaluating the potential to consolidate the day one and day 15 infusions of Briumvi into a single 600-mg infusion on day one. TG Therapeutics plans to announce pivotal topline data from the ENHANCE study in mid-year 2026.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for RMS in a pivotal phase III study. A self-injectable version of Briumvi could allow patients to administer doses themselves at their convenience, lowering the need for visits to medical centers for intravenous infusion. Pivotal topline data from the subcutaneous Briumvi (ublituximab) program are expected to be announced in late 2026 or the first quarter of 2027.
Besides Briumvi, TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis. Preliminary phase I data from the azer-cel study is expected to be announced in the second half of 2026.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. Shares of MNKD have declined 7.1% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.65 to $3.47. KROS shares have risen 87.1% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 54.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average earnings surprise being 20.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
Key Takeaways
TG Therapeutics’ (TGTX - Free Report) shares rose nearly 7% in after-hours trading, following the release of preliminary fourth-quarter and full-year 2025 results on Jan. 13, which beat expectations.
TGTX issued bullish guidance for 2026 and outlined some key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates.
TG Therapeutics’ top line primarily comprises product sales from Briumvi, along with royalty and other revenues. Briumvi is approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
Over the past year, TG Therapeutics shares have declined 7.7% against the industry’s growth of 18.7%.
Image Source: Zacks Investment Research
Q4 & FY2025 Preliminary Results
TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, exceeding the guidance of $600 million, provided with the third-quarter 2025 earnings release in November. The preliminary sales number also beat the Zacks Consensus Estimate of $604 million.
Briumvi U.S. net product revenues are expected to be approximately $182 million for the fourth quarter of 2025.
For full-year 2025, Briumvi net product sales are expected to be around $594 million in the United States, surpassing the company’s November guidance of around $585 million.
TGTX's 2026 Outlook & Pipeline Goals
TG Therapeutics expects worldwide total revenues in the range of $875 million to $900 million in 2026, including net product revenues of approximately $825 million to $850 million from Briumvi sales in the United States. The 2026 guidance range indicates potential double-digit year-over-year growth compared with the expected 2025 numbers.
TGTX expects operating expenses of around $350 million for the full year 2026.
In 2026, TGTX expects to advance several key milestones across its development pipeline. It recently completed patient enrollment in the phase III ENHANCE study which is evaluating the potential to consolidate the day one and day 15 infusions of Briumvi into a single 600-mg infusion on day one. TG Therapeutics plans to announce pivotal topline data from the ENHANCE study in mid-year 2026.
TG Therapeutics is developing a self-administered subcutaneous formulation of Briumvi for RMS in a pivotal phase III study. A self-injectable version of Briumvi could allow patients to administer doses themselves at their convenience, lowering the need for visits to medical centers for intravenous infusion. Pivotal topline data from the subcutaneous Briumvi (ublituximab) program are expected to be announced in late 2026 or the first quarter of 2027.
Besides Briumvi, TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in a phase I study for treating patients with primary progressive multiple sclerosis. Preliminary phase I data from the azer-cel study is expected to be announced in the second half of 2026.
TG Therapeutics’ Zacks Rank & Stocks to Consider
TGTX currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are MannKind (MNKD - Free Report) , Keros Therapeutics (KROS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. Shares of MNKD have declined 7.1% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.65 to $3.47. KROS shares have risen 87.1% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 54.3% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average earnings surprise being 20.21%.